東京大学医学部附属病院は、東京都文京区本郷七丁目にある東京大学医学部附属の大学病院。略称は東大病院。以前存在した同病院分院についても本記事内で解説する。

During the past decade, The University of Tokyo Hospital conducted 26 clinical trials. In the 10-year time frame, 26 clinical trials started and 12 clinical trials were completed, i.e. on average, 46.2% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 7 clinical trials were completed. i.e. 46.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The University of Tokyo Hospital" #1 sponsor was "Eli Lilly and Company" with 5 trials, followed by "Boehringer Ingelheim" with 4 trials sponsored, "Haruhiko Fukuda" with 3 trials sponsored, "Pfizer" with 3 trials sponsored and "AstraZeneca" with 3 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The University of Tokyo Hospital" #1 collaborator was "Eli Lilly and Company" with 4 trials as a collaborator, "Ministry of Health, Labour and Welfare, Japan" with 3 trials as a collaborator, "Accelerating Medicines Partnership (AMP)" with 2 trials as a collaborator, "Alzheimer's Association" with 2 trials as a collaborator and "Eisai Inc." with 2 trials as a collaborator. Other collaborators include 13 different institutions and companies that were collaborators in the rest 22 trials.

According to Clinical.Site data, the most researched conditions in "The University of Tokyo Hospital" are "Alzheimer Disease" (2 trials), "Alzheimers Disease" (2 trials), "Alzheimers Disease, Familial" (2 trials), "Chronic Kidney Disease" (2 trials) and "Dementia" (2 trials). Many other conditions were trialed in "The University of Tokyo Hospital" in a lesser frequency.

Most popular intervention types in "The University of Tokyo Hospital" are "Drug" (35 trials), "Biological" (3 trials), "Device" (2 trials), "Other" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "BI 685509" (2 trials), "E2814" (2 trials), "Empagliflozin" (2 trials) and "Lanabecestat" (2 trials). Other intervention names were less common.

The vast majority of trials in "The University of Tokyo Hospital" are 34 trials for "All" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "The University of Tokyo Hospital". undefined are not yet recruiting, 13 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in The University of Tokyo Hospital, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in The University of Tokyo Hospital, 3 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 26 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".